Ensysce Biosciences, Inc (ENSC): Price and Financial Metrics
ENSC Price/Volume Stats
| Current price | $0.55 | 52-week high | $7.20 |
| Prev. close | $0.56 | 52-week low | $0.53 |
| Day low | $0.54 | Volume | 59,700 |
| Day high | $0.58 | Avg. volume | 1,190,910 |
| 50-day MA | $0.78 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 4.01M |
ENSC Stock Price Chart Interactive Chart >
Ensysce Biosciences, Inc (ENSC) Company Bio
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.
Latest ENSC News From Around the Web
Below are the latest news stories about ENSYSCE BIOSCIENCES INC that investors may wish to consider to help them evaluate ENSC as an investment opportunity.
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 /Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 ... |
Ensysce Biosciences Announces Key Efficacy Data for Lead AnalgesicResults Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity ReductionPF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, ... |
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day PodcastPHOENIX, AZ / ACCESSWIRE / December 11, 2023 / The Stock Day Podcast welcomed Ensysce Biosciences (NASDAQ:ENSC) ("the Company"), a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs.CEO of the Company, ... |
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note FinancingAdditional Funding from Investors Validates Company's MissionSAN DIEGO, CA / ACCESSWIRE / November 29, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve ... |
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United StatesCollaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the ... |
ENSC Price Returns
| 1-mo | -31.25% |
| 3-mo | -64.97% |
| 6-mo | -46.08% |
| 1-year | -85.90% |
| 3-year | -99.98% |
| 5-year | N/A |
| YTD | -48.11% |
| 2023 | -88.22% |
| 2022 | -99.20% |
| 2021 | -62.20% |
| 2020 | -94.03% |
| 2019 | 6.11% |
Loading social stream, please wait...